Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (5): 575-587.doi: 10.12092/j.issn.1009-2501.2022.05.011

Previous Articles     Next Articles

Colorectal cancer and microRNA: research progress

ZHOU Guangchen1, LIU Yixi2, ZHENG Yun3   

  1. 1Faculty of Information Engineering and Automation, Kunming University of Science and Technology, Kunming 650500, Yunnan, China; 2The First Affiliated Hospital of Kunming Medical University, Yunnan Cardiovascular and Cerebrovascular Disease Clinical Medical Center, Kunming 650032, Yunnan, China; 3Institute of Primate Translational Medicine, State Key Laboratory of Non-Human Primate Biomedicine, Kunming University of Science and Technology, Kunming 650051, Yunnan, China
  • Received:2022-01-30 Revised:2022-04-06 Online:2022-05-26 Published:2022-06-06

Abstract:

Colorectal cancer (CRC) has a high incidence and mortality rate worldwide. Its lesions are associated to gene mutation, epigenetic changes and activation of related signaling pathways. microRNAs (miRNAs) are a class of non-coding RNAs of 20-24 nt in length that can regulate the expression of target mRNAs and control various cellular mechanisms. As a novel marker for the treatment and prognosis of colorectal cancer, miRNAs are closely related to the occurrence and progression of colorectal cancer. In this review, we summarize the miRNAs dysregulated in CRC tissues, analyze the relationship between specific miRNAs and CRC proliferation, metastasis, apoptosis, and chemotherapy, and present the clinical applications of miRNAs in CRC treatment and prognosis.

Key words: miRNA, colorectal cancer, biomarkers, regulation

CLC Number: